Oddo BHF downgraded Novo Nordisk to Neutral from Outperform. The analyst sees limited valuation upside and clinical news flow in the near-term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk reports FDA approved label expansion for Wegovy
- Novo Nordisk price target raised to DKK 1,100 from DKK 950 at Deutsche Bank
- Novo Nordisk price target raised to DKK 1,050 from DKK 900 at Barclays
- Novo Nordisk’s (NYSE:NVO) Wegovy Set to Storm China’s Weight Loss Market
- Major Stocks Scale New Highs as Indices Set New Records
